Optimizing mitochondria function in immune cells: implications for cancer immunotherapy
- PMID: 40962613
- DOI: 10.1016/j.trecan.2025.08.006
Optimizing mitochondria function in immune cells: implications for cancer immunotherapy
Abstract
The tumor microenvironment (TME) imposes profound metabolic and functional constraints on immune cells, with mitochondrial dysfunction emerging as a pivotal driver of immunosuppression. While mitochondrial metabolism is well recognized for its role in energy production and cellular homeostasis, its dynamic regulation of immune cell activation, differentiation, and exhaustion within the TME remains underexplored. In this review we summarize insights into how TME stressors such as hypoxia, nutrient competition, and metabolic byproducts subvert mitochondrial dynamics, redox balance, and mitochondrial DNA (mtDNA) signaling in T cells, natural killer (NK) cells, and macrophages, thereby directly impairing their antitumor efficacy. We emphasize that the restoration of mitochondrial fitness in immune cells, achieved by targeting metabolites in the TME and mitochondrial quality control, represents a pivotal axis for adoptive cell therapies (ACTs) and TME reprogramming.
Keywords: ROS; chimeric antigen receptor (CAR); metabolism; mitochondria; tumor immunotherapy.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.C. is a co-founder and shareholder of TargTex S.A. – Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US) and is on the Scientific Advisory board of Vector Bioscience Cambridge. The other authors have no conflicts of interest to declare.
Publication types
LinkOut - more resources
Full Text Sources